Elevated level of the soluble receptor for advanced glycation end-products involved in sarcopenia: an observational study

Table 1 Characteristics of Study Population

Variables	Male(n = 137)	Female(n = 177)	P value
Continuous variable (mean ± SD)^a
Age (years)	73.12 ± 8.41	71.82 ± 7.49	0.148
Grip strength (kg)	33.86 ± 8.05	20.23 ± 5.26	< 0.001
SMI (ALM/ht²)(kg/m²)	7.26 ± 0.79	5.79 ± 0.66	< 0.001
Gait speed(m/s)	1.13 ± 0.34	1.09 ± 0.30	0.330
Number of comorbidity.	0.77 ± 0.93	0.76 ± 1.02	0.922
AGE(μg/mL)	37.65 ± 17.80	37.48 ± 16.45	0.933
RAGE(pg/ml)	1204.24 ± 496.12	1280.28 ± 568.82	0.236
Categorical variable (%)^b
HTN	39.4%	31.1%	0.124
DM	10.9%	14.1%	0.403
MI	1.5%	0.6%	0.419
Angina	0.7%	1.1%	0.718
CAD	10.9%	5.1%	0.052
COPD	2.9%	5.6%	0.245

Abbreviations: AGE Advanced glycation end products, sRAGE soluble receptor for advanced glycation end-products, SMI skeletal muscle mass index, HTN hypertension, DM diabetes mellitus, MI myocardial infarction, CAD coronary artery disease, COPD chronic obstructive pulmonary disease
^aValues in the continuous variables were expressed as mean and standard deviation
^bValues in the categorical variables were expressed in number and percentage (%)
Pearson’s chi-square test was applied for comparison of categorical variables, whereas ANOVA (Analysis of Variance) was applied for comparison of continuous variables

ISSN: 1471-2318